Results 41 to 50 of about 1,789 (171)

“It’s already in your body and it’s preventing”: a qualitative study of African female adolescent’s acceptability and preferences for proxy HIV prevention methods in Cape Town, South Africa

BMC Public Health, 2023
Background Advances in biomedical HIV prevention will soon offer young women a choice of HIV prevention methods, including various pre-exposure prophylaxis (PrEP) modalities such as daily oral pills, dapivirine vaginal ring, and long-acting injectable ...
Lauren Fynn, Katherine Gill, Melissa Wallace, Millicent Atujuna, Menna Duyver, Penelope Ngcobo, Hans Spiegel, Alex Rinehart, Sybil Hosek, Linda-Gail Bekker   +9 more
doaj   +1 more source

Influence of dapivirine vaginal ring use on cervicovaginal immunity and functional microbiome in adolescent girls. [PDF]

AIDS, 2021
Objective: The antiretroviral-based dapivirine vaginal ring reduced HIV risk among women in phase III clinical trials. However, limited data exists on the impact of dapivirine on the vaginal microenvironment in adolescents. Design: A comprehensive metaproteomics approach was used to
Farr Zuend C, Noël-Romas L, Hoger S, McCorriser S, Westmacott G, Marrazzo J, Hillier SL, Dezzutti C, Squires K, Bunge KE, Burgener A.   +10 more
europepmc   +4 more sources

Dapivirine Vaginal Ring for HIV Prevention in Women in South Africa

Infectious Diseases, 2022
Young women remain disproportionately affected by the HIV epidemic in South Africa. Clinical trials have shown that the dapivirine vaginal ring (DVR) is safe and effective at reducing HIV infection in women. In March 2022, the South African Health Products Regulatory Authority approved the use of the DVR in women aged 18 years and older who are unable ...
Linda-Gail Bekker, Katherine Gill
openaire   +1 more source

Experiences with simultaneous use of contraception and the vaginal ring for HIV prevention in sub-Saharan Africa

BMC Women's Health, 2021
Background Clinical trials have found that a monthly dapivirine vaginal ring was well-tolerated and reduced HIV-1 risk among women in sub-Saharan Africa.
Jonah Leslie, Flavia Kiweewa, Thesla Palanee-Phillips, Katherine Bunge, Felix Mhlanga, Betty Kamira, Jared Baeten, Ariana Katz, Sharon Hillier, Elizabeth Montgomery, for the MTN-020/ASPIRE Study Team   +10 more
doaj   +1 more source

Impact and experience of participant engagement activities in supporting dapivirine ring use among participants enrolled in the phase III MTN-020/ASPIRE study

BMC Public Health, 2021
Background Low adherence to investigational products can negatively impact study outcomes, limiting the ability to demonstrate efficacy. To continue advancing potential new HIV prevention technologies, efforts are needed to improve adherence among study ...
Morgan Garcia, Ellen Luecke, Ashley J. Mayo, Rachel Scheckter, Patrick Ndase, Flavia Matovu Kiweewa, Doreen Kemigisha, Petina Musara, Leila E. Mansoor, Nishanta Singh, Kubashni Woeber, Neetha S. Morar, Nitesha Jeenarain, Zakir Gaffoor, Daniel K. Gondwe, Yvonne Makala, Llewellyn Fleurs, Krishnaveni Reddy, Thesla Palanee-Phillips, Jared M. Baeten, Ariane van der Straten, Lydia Soto-Torres, Kristine Torjesen   +22 more
doaj   +1 more source

Transport and Permeation Properties of Dapivirine: Understanding Potential Drug-Drug Interactions

Pharmaceutics, 2022
The dapivirine (DPV) vaginal ring was developed by the nonprofit International Partnership for Microbicides (IPM) for reducing the risk of HIV infection.
Ruohui Zheng, Guru R. Valicherla, Junmei Zhang, Jeremy Nuttall, Peter Silvera, Leslie J. Marshall, Philip E. Empey, Lisa C. Rohan   +7 more
doaj   +1 more source

Planning for decentralized, simplified prEP: Learnings from potential end users in Ga-Rankuwa, gauteng, South Africa

Frontiers in Reproductive Health, 2023
BackgroundIn South Africa, youth experience challenges with oral Pre-Exposure Prophylaxis (PrEP) access and uptake. Taking services out of healthcare settings has the potential to increase reach and overcome these challenges.
Paballo Mataboge, Susan Nzenze, Nqaba Mthimkhulu, Mbali Mazibuko, Alison Kutywayo, Vusile Butler, Nicolette Naidoo, Saiqa Mullick   +7 more
doaj   +1 more source

Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial. [PDF]

J Int AIDS Soc, 2020
Brown ER, Hendrix CW, van der Straten A, Kiweewa FM, Mgodi NM, Palanee-Philips T, Marzinke MA, Bekker LG, Soto-Torres L, Hillier SL, Baeten JM, MTN-020/ASPIRE Study Team.   +11 more
europepmc   +2 more sources

Polymeric gels for intravaginal drug delivery [PDF]

, 2017
This document is the Accepted Manuscript version of the following article: Michael T. Cook, and Marc b. Brown, ‘Polymeric gels for intravaginal drug delivery’, Journal of Controlled Release, Vol. 270: 145-157, January 2018. Under embargo until 6 December
Brown, Marc, Cook, Michael
core   +2 more sources

Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention.

PLoS ONE, 2015
IntroductionWomen in sub-Saharan Africa are a priority population for evaluation of new biomedical HIV-1 prevention strategies. Antiretroviral pre-exposure prophylaxis is a promising prevention approach; however, clinical trials among young women using ...
Thesla Palanee-Phillips, Katie Schwartz, Elizabeth R Brown, Vaneshree Govender, Nyaradzo Mgodi, Flavia Matovu Kiweewa, Gonasagrie Nair, Felix Mhlanga, Samantha Siva, Linda-Gail Bekker, Nitesha Jeenarain, Zakir Gaffoor, Francis Martinson, Bonus Makanani, Sarita Naidoo, Arendevi Pather, Jessica Phillip, Marla J Husnik, Ariane van der Straten, Lydia Soto-Torres, Jared Baeten   +20 more
doaj   +1 more source